Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 16/20 | 0.52 |
| ▸ | CASP6 | P55212 | 14/20 | 0.52 |
| ▸ | CASP8 | Q14790 | 14/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7201528 | 0.86 | CASP3 (0.35) | CASP3CASP6CASP8MEN1RAB9A | |
| SCHEMBL7203863 | 0.82 | CASP3 (0.48) | CASP3CASP6CASP8 | |
| SCHEMBL7671265 | 0.82 | CASP3 (0.52) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL7201585 | 0.81 | MAPT (0.32) | CASP3CASP6CASP8MEN1RAB9A | |
| SCHEMBL7678676 | 0.78 | CACNA1B (0.32) | RAB9A | |
| SCHEMBL7202668 | 0.78 | CASP3 (0.53) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL5667678 | 0.74 | CASP3 (0.62) | CASP3CASP6CASP8 | |
| SCHEMBL311790 | 0.68 | CASP3 (0.62) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL10044272 | 0.68 | CASP3 (0.62) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL6505861 | 0.67 | CASP3 (0.65) | CASP3CASP6CASP8KMT2ACASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6489353-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; CENTRAL NERVOUS SYSTEM DISORDERS | IDUN PHARMACEUTICALS, INC. | 2002-12-03 | — | — | US | disclosed |
| US-20020025935-A1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 2002-02-28 | — | — | US | disclosed |
| US-6184244-B1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. | 2001-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025935-A1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CASP3, CASP1, IAPP | CASP3 1/4885CASP6 37/4885CASP8 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.